Hippocampal volume and the AKT signaling system in first-episode schizophrenia

Journal of Psychiatric Research

Volumn 46, Issue 3, 2012, Pages 279-284

  Szamosi, András ^a   Kelemen, Oguz ^b   Kéri, Szabolcs ^a,c  

^a National Psychiatry Center   (Hungary)

^b BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

AKT system; Hippocampus; Neuregulin 1; Schizophrenia

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; LYMPHOBLAST; MALE; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84857141655     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.12.005     Document Type: Article

References (54)

1. Abe Y., Namba H., Kato T., Iwakura Y., Nawa H. Neuregulin-1 signals from the periphery regulate AMPA receptor sensitivity and expression in GABAergic interneurons in developing neocortex. Journal of Neuroscience 2011, 31:5699-5709.
2. Adriano F., Caltagirone C., Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 2011 Apr 29, doi: 10.1177/1073858410395147.
3. Balog Z., Kiss I., Kéri S. CACNA1C risk allele for psychotic disorders is related to the activation of the AKT-pathway. American Journal of Psychiatry 2010, 167:1276-1277.
4. Balu D.T., Carlson G.C., Talbot K., Kazi H., Hill-Smith T.E., Easton R.M., et al. Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus 2010 Nov 3, 10.1002/hipo.20887.
5. Beaulieu J.M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Journal of Psychiatry and Neuroscience 2011, 36:110011. doi: 10.1503/jpn.110011.
6. Bellon A. New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. Molecular Psychiatry 2007, 12:620-629.
7. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011 Oct 19, doi: 10.1038/nature10603.
8. Buehlmann E., Berger G.E., Aston J., Gschwandtner U., Pflueger M.O., Borgwardt S.J., et al. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. Journal of Psychiatric Research 2010, 44:447-453.
9. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Research Bulletin 2010, 83:122-131.
10. Chakos M.H., Schobel S.A., Gu H., Gerig G., Bradford D., Charles C., et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. British Journal of Psychiatry 2005, 186:26-31.
11. Ebdrup B.H., Glenthøj B., Rasmussen H., Aggernaes B., Langkilde A.R., Paulson O.B., et al. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. Journal of Psychiatry and Neuroscience 2010, 35:95-104.
12. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. American Journal of Psychiatry 2008, 165:1015-1023.
13. Fazzari P., Paternain A.V., Valiente M., Pla R., Luján R., Lloyd K., et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 2010, 464:1376-1380.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Washington, DC.
15. Fischl B., Salat D.H., van der Kouwe A.J., Makris N., Ségonne F., Quinn B.T., et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004, 23(Suppl. 1):S69-S84.
16. Freedman R., Goldowitz D. Studies on the hippocampal formation: from basic development to clinical applications: studies on schizophrenia. Progress in Neurobiology 2010, 90:263-275.
17. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. American Journal of Psychiatry 2010, 167:388-396.
18. Fusar-Poli P., Borgwardt S., Crescini A., Deste G., Kempton M.J., Lawrie S., et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neuroscience and Biobehavioral Reviews 2011, 35:1175-1185.
19. Geuze E., Vermetten E., Bremner J.D. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Molecular Psychiatry 2005, 10:160-184.
20. Gruber O., Falkai P., Schneider-Axmann T., Schwab S.G., Wagner M., Maier W. Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. Journal of Psychiatric Research 2008, 43:1-6.
21. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biological Psychiatry 2006, 60:132-140.
22. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Current Topics in Behavioural Neurosciences 2010, 4:529-553.
23. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 2005, 162:2233-2245.
24. Kalkman H.O. The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacology & Therapeutics 2006, 110:117-134.
25. Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., Lizardi-Ortiz J.E., et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences 2010, 31:381-390.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
27. Kéri S., Seres I., Kelemen O., Benedek G. Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. Neurochemistry International 2009, 55:606-609.
28. Kéri S., Beniczky S., Kelemen O. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. American Journal of Psychiatry 2010, 167:444-450.
29. Kéri S., Seres I., Kelemen O., Benedek G. The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in nonclinical individuals. Schizophrenia Bulletin 2011, 37:141-147.
30. Keshet Y., Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods in Molecular Biology 2010, 661:3-38.
31. Kvajo M., McKellar H., Gogos J.A. Molecules, signaling, and schizophrenia. Current Topics in Behavioural Neurosciences 2010, 4:629-656.
32. Lewis D.A., González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33:141-165.
33. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences 2008, 31:234-242.
34. Lodge D.J., Grace A.A. Developmental pathology, dopamine, stress and schizophrenia. International Journal of Developmental Neurosciences 2011, 29:207-213.
35. Mahar I., Tan S., Davoli M.A., Dominguez-Lopez S., Qiang C., Rachalski A., et al. Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-like effects. PLoS One 2011, 6:e26610.
36. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Review Neurosciences 2008, 9:437-452.
37. Mondelli V., Pariante C.M., Navari S., Aas M., D'Albenzio A., Di Forti M., et al. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophrenia Research 2010, 119:75-78.
38. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Archives of General Psychiatry 1998, 55:433-440.
39. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics 2008, 40:1053-1055.
40. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., et al. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophrenia Research 2011, 129:201-204.
41. Rösler T.W., Depboylu C., Arias-Carrión O., Wozny W., Carlsson T., Höllerhage M., et al. Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1. Neuropharmacology 2011, 61:1413-1418.
42. Schmitt A., Parlapani E., Gruber O., Wobrock T., Falkai P. Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:35-39.
43. Segonne F., Dale A.M., Busa E., Glessner M., Salat D., Hahn H.K., et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004, 22:1060-1075.
44. Sei Y., Ren-Patterson R., Li Z., Tunbridge E.M., Egan M.F., Kolachana B.S., et al. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Molecular Psychiatry 2007, 12:946-957.
45. Sei Y., Li Z., Song J., Ren-Patterson R., Tunbridge E.M., Iizuka Y., et al. Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. PLoS One 2010, 5:e10789.
46. Seres I., Kelemen O., Benedek G., Kéri S. Neuregulin 1-induced AKT phosphorylation in monozygotic twins discordant for schizophrenia. Neurochemistry International 2010, 56:906-910.
47. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 2006, 188:510-518.
48. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. American Journal of Psychiatry 2010, 167:1178-1193.
49. Tan H.Y., Chen A.G., Chen Q., Browne L.B., Verchinski B., Kolachana B., et al. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Molecular Psychiatry 2011 Jul 26, doi: 10.1038/mp.2011.91.
50. The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 2011, 43:969-976.
51. Ting A.K., Chen Y., Wen L., Yin D.M., Shen C., Tao Y., et al. Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. Journal of Neuroscience 2011, 31:15-25.
52. Vita A., De Peri L., Silenzi C., Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophrenia Research 2006, 82:75-88.
53. Witthaus H., Mendes U., Brüne M., Ozgürdal S., Bohner G., Gudlowski Y., et al. Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia. Journal of Psychiatry and Neuroscience 2010, 35:33-40.
54. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000, 157:16-25.